Awareness Capital Research
Investment Thesis
Awareness Capital is a thesis-led venture capital firm dedicated exclusively to brain and mental health. The firm's stated mission is "Advancing the Next Generation of Brain & Mental Health Companies," addressing what it calls the "translational gap" between scientific research and real-world clinical impact. The firm targets scalable, AI-enabled companies translating breakthrough science into diagnostics, therapeutics, and care delivery. Awareness Capital frames brain health as a $1 trillion+ addressable market that receives disproportionately low R&D investment relative to its global burden — the firm cites 970+ million people affected globally, with 75% of conditions untreated in low-to-middle-income countries. The firm operates on three guiding principles: scientific rigor grounded in evidence rather than momentum, human-centered urgency, and pursuit of enduring clinical and societal value. It positions itself in a category it says fewer than 2% of VC firms actively invest in.
Stage Focus
Per the firm's FAQ, Awareness Capital targets early-to-growth-stage companies spanning Seed through Series B, focusing on organizations with clinical or commercial traction beyond pure research. The homepage emphasizes "mid-stage companies with early traction and validated models — reducing early-stage risk while preserving exposure to high-growth outcomes," suggesting a preference for Series A/B over pure pre-seed, though the portfolio includes several Seed-stage bets (Hemispheric, Sanmai, LunaJoy, Benchmark Health, Metabolic Psychiatry Labs, Ampa, Gilgamesh).
Check Size
Not publicly disclosed on the website, FAQ, or in available secondary sources (PitchBook, Private Equity International, SEC IAPD summary). No specific check-size range could be verified.
Lead Tendency
The FAQ states the firm "can lead or co-invest depending on the opportunity, stage, and existing syndicate composition," indicating a flexible, both-lead-and-follow posture rather than a strict lead mandate.
Recent Activity
Awareness Capital (via its OneMind/Awareness Capital vehicle) participated in Hemispheric's $52M stealth-emergence round announced July 15, 2026, alongside Hanaco Ventures, Protocol Labs, L Catterton, Arkin Capital, OurCrowd, Artofin VC, and individual investors including Howard Morgan and Scott Belsky. Hemispheric builds Descartes, a frontier NeuroAI model for decoding non-invasive EEG brain activity to support diagnosis of PTSD, depression, and Alzheimer's. Separately, portfolio company Gilgamesh Pharmaceuticals realized a major exit event in August 2025 when AbbVie agreed to acquire its lead psychedelic asset bretisilocin (GM-2505) for up to $1.2B. Portfolio company Ampa also closed an oversubscribed $8.5M funding round in October 2025 to launch its FDA-cleared portable TMS brain-stimulation system nationally (lead investor not confirmed as Awareness Capital, but included here as a portfolio milestone). The firm's strategic partner, One Mind, continues to run an accelerator program whose alumni (Ampa, LunaJoy, Metabolic Psychiatry Labs, Sanmai) overlap heavily with Awareness Capital's stated portfolio.
Portfolio Highlights
Fifteen companies are listed on the firm's public portfolio page, spanning AI-enabled mental health diagnostics, psychedelic and neuromodulation therapeutics, and care-delivery platforms: Ellipsis Health (AI voice screening for mental health conditions), Two Chairs (tele-psychiatry platform covered by leading insurers), Cybin Inc. (publicly traded psychedelics-based therapeutics developer), Magnus Medical (neurostimulation therapy for treatment-resistant depression), Holobiome (microbiome-based therapeutics for depression, anxiety, and chronic pain), CredibleMind (employer/HR mental health resource portals), Hemispheric (NeuroAI brain-decoding platform, recently emerged from stealth with $52M), Sanmai (transcranial ultrasound + AI neurotherapeutics), LunaJoy (specialty women's mental health platform), Benchmark Health (mental health marketplace/matching service co-founded by former NIMH director Tom Insel), Metabolic Psychiatry Labs (metabolic-science-based psychiatric care), Cognitive Scientific AI (cognitive-architecture AI platform), Ampa (portable FDA-cleared TMS brain stimulation device), Wisdo Health (online peer support platform, noted as exited), and Gilgamesh Pharmaceuticals (psychedelic therapeutics, whose lead depression asset was acquired by AbbVie for up to $1.2B in 2025).
Team
- Charles Finnie, Managing Partner — veteran enterprise-software and AI investor; led early bets in C3.ai, Ask Jeeves, Kana, and Macromedia; also affiliated with EFW Partners.
- Garen Staglin, General Partner (Fund I) & Advisor — philanthropist-investor; co-founded the mental health nonprofit One Mind, Awareness Capital's strategic partner.
- Gwill York, General Partner — co-founder of Cambridge Associates; long-time advocate for neurodiversity and brain-health innovation.
- Kathy Guerry, CFO — financial executive with 30+ years supporting entrepreneurial companies and investment funds.
- Dr. Joshua Chauvin, Venture Partner — entrepreneur and cognitive neuropsychologist with two decades of global mental health experience.
The firm also draws on a deep bench of scientific and clinical advisors, including Tom Insel (former NIMH Director), Prof. Husseini Manji, Steven Hyman (Stanley Center, Harvard), Prof. Richard Huganir (Johns Hopkins), Dr. Eric Nestler, Prof. Robert Malenka, Dr. Michelle Tempest, Dr. Jerry Rosenbaum (Harvard Medical School / Mass General), and strategic advisor Aahuti Rai.
Decision Process
Four managing/general partners drive investment decisions, supported by a formal four-step diligence framework: (1) signal sourcing via scientific advisors and sector experts, (2) rigorous scientific/mechanistic vetting, (3) operational-feasibility and regulatory audit, and (4) decision paired with active portfolio support. This structure points to a partnership-style decision process rather than a solo-GP model.
Founder Preferences
The firm explicitly favors "clarity over choreography" — substantive first conversations over polished pitches — and prioritizes translation, evidence, and relevance over momentum-driven narratives. It is drawn to founders building on credible science with a defensible path from technical promise to operating reality.
Geographic Focus
Headquartered in the United States (Westport, Massachusetts, per third-party sources; not disclosed directly on the firm's own site). While the firm evaluates opportunities globally, it shows particular interest in companies with a clear path to the U.S. market, citing regulatory clarity and reimbursement infrastructure as key advantages.